In 33 patients with glioblastoma multiforme who were treated with the new vaccine IGV-001, the longer progression-free survival as well as the longer overall survival were observed  compared to the control group.

Professor David Andrews who conducted the research and has been treating glioblastoma patients for decades said that promising results of the phase Ib trial encourage him to initiating a phase II trial even this year.

The new vaccine is a personalized one created from the patient’s own tumor cells sampled during surgical operation.

More about the new vaccine here